HCM
HUTCHMED (China) Limited
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · HK
$14.17
+0.43%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−58.7x
Market Cap
$2.47B
MomentumView details →
1D Return
+0.43%
YTD Return
+5.93%
RSI (14)
74.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−58.7x
Market Cap
$2.47B
RSI (14)
74.2
MomentumView details →
1D Return
+0.43%
YTD Return
+5.93%
SummaryUpdated Jun 1, 2026
HUTCHMED (China) Limited (NASDAQ:HCM) is a Hong Kong-based biopharmaceutical company that was founded in 2000 and went public in 2016. Originally known as Hutchison China MediTech Limited, the company rebranded to HUTCHMED in May 2021. The company specializes in discovering, developing, and commercializing targeted cancer therapies and immunological treatments, with operations spanning Hong Kong and international markets. HUTCHMED has evolved from a research-focused organization into a commercial-stage company with multiple approved drugs and a robust pipeline of investigational treatments.
Similar companies
Latest newsMore news →
AstraZeneca reported positive late-stage trial results for a combination of its lung cancer drugs Tagrisso and Orpathys, potentially paving the way for global approval.19d agoHUTCHMED received NMPA approval for ORPATHYS® for the treatment of gastric cancer patients with MET amplification in China.64d ago